drugset
drugset / Trial / NCT05761366

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

NCT05761366 ↗

Phase 2 Recruiting 400 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelDiagnostic

Summary

In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.

Timeline

Start
2022-10-13
Primary completion
2025-10-13
Completion
2025-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Al18F-PSMA-BCH Unknown — Intravenous

Indications

cancer